Press Release: PatientCraft Publishes Results of 340B Stakeholders Survey [...]
The 340B drug pricing program, enacted in 1992, provides discounts on outpatient drugs to safety-net providers (called 340B covered entities) who meet certain qualifications. Covered entities use the savings from the program to stretch scarce federal resources and invest in patient care.
PatientCraft, a healthcare consulting firm specializing in 340B program optimization, audit readiness and compliance, today announced the addition of industry expert, Holly Russo, RN, MSN, MSECS, as its new president and CEO. With the appointment of Russo, the company is also moving its corporate office from Dallas to El Paso.
There is a great opportunity for Accountable Care Organizations (ACOs) to take advantage of and partner with covered entities that are eligible for 340B drug pricing.
Today we face some of the most significant changes in payment policy, and an increased focus on quality of care to outcome and reimbursement.
Last month, the Government Accountability Office (GAO) issued a critical report on the 340B program. GAO interviewed 61 stakeholders in the program about their ability to generate savings and distribute drugs. GAO also examined the adequacy of federal oversight of the program.